It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...
Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...
GlobalData on MSN10d
Biosimilars drive Sandoz growth ahead of unclear tariff effects in 2025Looking ahead to 2025, Sandoz said it expects net sales to grow by a mid-single digit percentage in constant currencies.
Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...
Regulatory reforms that improve the competitive landscape for biosimilars will promote drug affordability while incentivizing ...
A Matrix Global Advisors report highlights current barriers and recommendations for robust competition and patient savings in ...
The latest research report published by Vantage Market Research, titled "An Increase in Demand and Opportunities for the Global Biosimilars Market 2025-2035," provides a comprehensive analysis of the ...
The company emphasized its strategic focus on biosimilars, noting significant investments and a robust pipeline targeting a $200 billion market. While Alvotech highlighted successful product ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
PORTLAND, OR, UNITED STATES, March 11, 2025 /EINPresswire / -- The biosimilar testing and development services market is experiencing rapid growth, projected to surge from $2.5 billion in 2022 to ...
South Korean biopharmaceutical company Celltrion announced Thursday that it has launched Steqeyma (ustekinumab), a biosimilar treatment for autoimmune diseases, in the US market. Steqeyma, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback